{"classes":[{"categories":[{"measurements":[{"comment":"Only 1 participant with available measurements at baseline and 88 weeks","groupId":"OG000","spread":"NA","value":"8.70"},{"comment":"Only 1 participant with available measurements at baseline and 93 weeks","groupId":"OG001","spread":"NA","value":"63.03"},{"comment":"Only 1 participant with available measurements at baseline and 25 weeks","groupId":"OG002","spread":"NA","value":"-39.49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"mSWAT is a scoring technique involving the direct assessment of the percentage of body-surface-area (BSA) affected by skin lesions.\n\nThere are 12 body regions (each one assigned a different percentage of BSA). For each body region, the assigned BSA percentage is multiplied by a factor weighing the type and severity of lesion observed (patch= x1, plaque = x2, tumor= x4).\n\nThe sum of the individual body region sub-scores is then summed to generate the final mSWAT score, which ranges from 0 (best outcome) to 400 (worst outcome).","dispersionType":"Standard Deviation","groups":[{"description":"3mg/kg of nivolumab","id":"OG000","title":"Nivolumab Monotherapy (Expansion)"},{"description":"3 mg/kg of nivolumab and\n\n1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W","id":"OG002","title":"Nivolumab + Lirilumab"}],"paramType":"MEAN","populationDescription":"All Treated Participants with cutaneous T Cell lymphoma and available measurements","reportingStatus":"POSTED","timeFrame":"From baseline (last measurement before start of study treatment) to last available measurement after start of study treatment (88 weeks for Nivo mono, 93 weeks for nivo+ipi, 25 weeks for nivo+liri)","title":"Percentage Change From Baseline in the Modified Severity Weighted Assessment Tool (mSWAT) Score","type":"SECONDARY","unitOfMeasure":"Percent of change from baseline"}